(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 August 2010 (12.08.2010)

PCT

(10) International Publication Number
WO 2010/090737 A1

(51) International Patent Classification:
A01N 43/58 (2006.01) *A61K 31/50* (2006.01)

(21) International Application Number:
PCT/US2010/000307

(22) International Filing Date:
4 February 2010 (04.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/202,207 5 February 2009 (05.02.2009) US
61/213,927 30 July 2009 (30.07.2009) US

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TANIGUCHI, Takahiko** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP). **KAWADA, Akira** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP). **KONDO, Mitsuyo** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP). **QUINN, John, F.** [US/US]; c/o Albany Molecular Research, Inc., 26, Corporate Circle, P. O. Box 15098, Albany, NY 12212-5098 (US). **KUNITOMO, Jun** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP). **YOSHIKAWA, Masato** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP). **FUSHIMI, Makoto** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 (JP).


(74) Agent: **CHEEK, Warren, M.**; Wenderoth, Lind & Ponack, LLP., 1030 15th Street, N.W., Suite 400 East, Washington, DC 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PYRIDAZINONE COMPOUNDS



(I_0)

(57) Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I_0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted,or a salt thereof.

WO 2010/090737 A1

Published:

— *with international search report (Art. 21(3))*